DNA Methyltransferases in Hematologic Malignancies

Seminars in Hematology

Volumn 50, Issue 1, 2013, Pages 48-60

  Li, Keqin Kathy ^a   Luo, Liu Fei ^a   Shen, Yang ^a   Xu, Jie ^a   Chen, Zhu ^a   Chen, Sai Juan ^a  

^a SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; DNA METHYLTRANSFERASE; DNA METHYLTRANSFERASE 1; DNA METHYLTRANSFERASE 2; DNA METHYLTRANSFERASE 3; DNA METHYLTRANSFERASE 3A; DNA METHYLTRANSFERASE 3B; DNA METHYLTRANSFERASE 3L; DNA METHYLTRANSFERASE INHIBITOR; FLUCYTOSINE DEOXYRIBOSIDE; HYDRALAZINE; N PHTHALOYLTRYPTOPHAN; PROCAINE; UNCLASSIFIED DRUG; VORINOSTAT; ZEBULARINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADVANCED CANCER; ARTICLE; BREAST CANCER; CANCER PROGNOSIS; CANCER STEM CELL; CARCINOGENESIS; CELL DIFFERENTIATION; CELL RENEWAL; CHRONIC MYELOID LEUKEMIA; COMPLEX FORMATION; DISEASE ASSOCIATION; DNA METHYLATION; DNMT3A GENE; DRUG APPROVAL; DRUG DESIGN; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG RESEARCH; DRUG SAFETY; DRUG STRUCTURE; DRUG TARGETING; DRUG TOLERABILITY; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME SPECIFICITY; EPIGENETICS; EVENT FREE SURVIVAL; FOOD AND DRUG ADMINISTRATION; GENE EXPRESSION REGULATION; GENE MUTATION; GENE REPRESSION; GENETIC HETEROGENEITY; GENETIC POLYMORPHISM; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LEUKEMOGENESIS; MOLECULAR INTERACTION; MOLECULAR PATHOLOGY; MYELODYSPLASTIC SYNDROME; NONHODGKIN LYMPHOMA; NONHUMAN; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN EXPRESSION; SOLID TUMOR; SOMATIC MUTATION; UNSPECIFIED SIDE EFFECT;

ANIMALS; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; DNA METHYLATION; ENZYME INHIBITORS; EPIGENESIS, GENETIC; HEMATOLOGIC NEOPLASMS; HUMANS; MODELS, MOLECULAR; MOLECULAR TARGETED THERAPY; MUTATION;

EID: 84875304496     PISSN: 00371963     EISSN: 15328686     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2013.01.005     Document Type: Article

References (95)

1. Hudson T.J., Anderson W., Artez A., et al. International network of cancer genome projects. Nature 2010, 464(7291):993-998.
2. Ledford H. Big science: The cancer genome challenge. Nature 2010, 464(7291):972-974.
3. Collins F.S., Barker A.D. Mapping the cancer genome. Pinpointing the genes involved in cancer will help chart a new course across the complex landscape of human malignancies. Sci Am 2007, 296(3):50-57.
4. Dickson D. Wellcome funds cancer database. Nature 1999, 401(6755):729.
5. Mardis E.R., Ding L., Dooling D.J., et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med 2009, 361(11):1058-1066.
6. Ding L., Wendl M.C., Koboldt D.C., Mardis E.R. Analysis of next-generation genomic data in cancer: accomplishments and challenges. Hum Mol Genet 2010, 19(R2):15.
7. Meyerson M., Gabriel S., Getz G. Advances in understanding cancer genomes through second-generation sequencing. Nat Rev Genet 2010, 11(10):685-696.
8. Summerer D., Schracke N., Wu H., et al. Targeted high throughput sequencing of a cancer-related exome subset by specific sequence capture with a fully automated microarray platform. Genomics 2010, 95(4):241-246.
9. Cronin M., Ross J.S. Comprehensive next-generation cancer genome sequencing in the era of targeted therapy and personalized oncology. Biomark Med 2011, 5(3):293-305.
10. Gilliland D.G., Jordan C.T., Felix C.A. The molecular basis of leukemia. Hematology Am Soc Hematol Educ Program 2004, 80-97.
11. Kaushansky K., Williams W.J. Hematopoietic Stem cells, Progenitor cells, and Cytokines. Williams Hematology 2010, 153-175. McGraw-Hill Medical, New York. 8th ed.
12. van Haaften G., Dalgliesh G.L., Davies H., et al. Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer. Nat Genet 2009, 41(5):521-523.
13. Pratcorona M., Abbas S., Sanders M.A., et al. Acquired mutations in ASXL1 in acute myeloid leukemia: prevalence and prognostic value. Haematologica 2011, 97(3):388-392.
14. Nikoloski G., Langemeijer S.M.C., Kuiper R.P., et al. Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes. Nat Genet 2010, 42(8):665-667.
15. Morin R.D., Johnson N.A., Severson T.M., et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat Genet 2010, 42(2):181-185.
16. Ernst T., Chase A.J., Score J., et al. Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat Genet 2010, 42(8):722-726.
17. Abdel-Wahab O., Pardanani A., Patel J., et al. Concomitant analysis of EZH2 and ASXL1 mutations in myelofibrosis, chronic myelomonocytic leukemia and blast-phase myeloproliferative neoplasms. Leukemia 2011, 25(7):1200-1202.
18. Yan X.-J., Xu J., Gu Z.-H., et al. Exome sequencing identifies somatic mutations of DNA methyltransferase gene DNMT3A in acute monocytic leukemia. Nat Genet 2011, 43(4):309-315.
19. Yamashita Y., Yuan J., Suetake I., et al. Array-based genomic resequencing of human leukemia. Oncogene 2010, 29(25):3723-3731.
20. Ley T.J., Ding L., Walter M.J., et al. DNMT3A mutations in acute myeloid leukemia. N Engl J Med 2010, 363(25):2424-2433.
21. Delhommeau F., Dupont S., Valle V.D., et al. Mutation in TET2 in myeloid cancers. N Engl J Med 2009, 360(22):2289-2301.
22. Bestor T.H. The DNA methyltransferases of mammals. Hum Mol Genet 2000, 9(16):2395-2402.
23. Hansen R.S., Wijmenga C., Luo P., et al. The DNMT3B DNA methyltransferase gene is mutated in the ICF immunodeficiency syndrome. Proc Natl Acad Sci U S A 1999, 96(25):14412-14417.
24. Xu G.L., Bestor T.H., Bourc'his D., et al. Chromosome instability and immunodeficiency syndrome caused by mutations in a DNA methyltransferase gene. Nature 1999, 402(6758):187-191.
25. Razin A., Riggs A.D. DNA methylation and gene function. Science 1980, 210(4470):604-610.
26. Laurent L., Wong E., Li G., et al. Dynamic changes in the human methylome during differentiation. Genome Res 2010, 20(3):320-331.
27. Lister R., Pelizzola M., Dowen R.H., et al. Human DNA methylomes at base resolution show widespread epigenomic differences. Nature 2009, 462(7271):315-322.
28. Ji H., Ehrlich L.I., Seita J., et al. Comprehensive methylome map of lineage commitment from haematopoietic progenitors. Nature 2010, 467(7313):338-342.
29. Hata K., Okano M., Lei H., Li E. Dnmt3L cooperates with the Dnmt3 family of de novo DNA methyltransferases to establish maternal imprints in mice. Development 2002, 129(8):1983-1993.
30. Okano M., Bell D.W., Haber D.A., Li E. DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell 1999, 99(3):247-257.
31. Illingworth R., Kerr A., Desousa D., et al. A novel CpG island set identifies tissue-specific methylation at developmental gene loci. PLoS Biol 2008, 6(1):e22.
32. Song J., Rechkoblit O., Bestor T.H., Patel D.J. Structure of DNMT1-DNA complex reveals a role for autoinhibition in maintenance DNA methylation. Science 2010, 331(6020):1036-1040.
33. Song J., Teplova M., Ishibe-Murakami S., Patel D.J. Structure-based mechanistic insights into DNMT1-mediated maintenance DNA nmethylation. Science 2012, 335(6069):709-712.
34. Broske A.M., Vockentanz L., Kharazi S., et al. DNA methylation protects hematopoietic stem cell multipotency from myeloerythroid restriction. Nat Genet 2009, 41(11):1207-1215.
35. Trowbridge J.J., Snow J.W., Kim J., Orkin S.H. DNA methyltransferase 1 is essential for and uniquely regulates hematopoietic stem and progenitor cells. Cell Stem Cell 2009, 5(4):442-449.
36. Goll M.G., Kirpekar F., Maggert K.A., et al. Methylation of tRNAAsp by the DNA methyltransferase homolog Dnmt2. Science 2006, 311(5759):395-398.
37. Schaefer M., Lyko F. Solving the Dnmt2 enigma. Chromosoma 2010, 119(1):35-40.
38. Dhayalan A., Rajavelu A., Rathert P., et al. The Dnmt3a PWWP domain reads histone 3 lysine 36 trimethylation and guides DNA methylation. J Biol Chem 2010, 285(34):26114-26120.
39. Kursula P., Wu H., Zeng H., et al. Structural and histone binding ability characterizations of human PWWP domains. PLoS ONE 2011, 6(6):e18919.
40. Jia D., Jurkowska R.Z., Zhang X., Jeltsch A., Cheng X. Structure of Dnmt3a bound to Dnmt3L suggests a model for de novo DNA methylation. Nature 2007, 449(7159):248-251.
41. Ooi S.K., Qiu C., Bernstein E., et al. DNMT3L connects unmethylated lysine 4 of histone H3 to de novo methylation of DNA. Nature 2007, 448(7154):714-717.
42. Otani J., Nankumo T., Arita K., Inamoto S., Ariyoshi M., Shirakawa M. Structural basis for recognition of H3K4 methylation status by the DNA methyltransferase 3A ATRX-DNMT3-DNMT3L domain. EMBO Rep 2009, 10(11):1235-1241.
43. Chodavarapu R.K., Feng S., Bernatavichute Y.V., et al. Relationship between nucleosome positioning and DNA methylation. Nature 2010, 466(7304):388-392.
44. Walter M.J., Ding L., Shen D., et al. Recurrent DNMT3A mutations in patients with myelodysplastic syndromes. Leukemia 2011, 25(7):1153-1158.
45. Ewalt M., Galili N., Mumtaz M., et al. DNMT3a mutations in high-risk myelodysplastic syndrome parallel those found in acute myeloid leukemia. Blood Cancer J 2011, 1(e9):1-3.
46. Cheng X., Blumenthal R.M. Mammalian DNA methyltransferases: a structural perspective. Structure 2008, 16(3):341-350.
47. Mizuno S., Chijiwa T., Okamura T., et al. Expression of DNA methyltransferases DNMT1, 3A, and 3B in normal hematopoiesis and in acute and chronic myelogenous leukemia. Blood 2001, 97(5):1172-1179.
48. Ehrlich M., Buchanan K.L., Tsien F., et al. DNA methyltransferase 3B mutations linked to the ICF syndrome cause dysregulation of lymphogenesis genes. Hum Mol Genet 2001, 10(25):2917-2931.
49. Bourc'his D., Xu G.L., Lin C.S., Bollman B., Bestor T.H. Dnmt3L and the establishment of maternal genomic imprints. Science 2001, 294(5551):2536-2539.
50. Lu J., Kong X., Luo C., Li K. Application of epigenome-modifying small molecules in induced pluripotent stem cells. Med Res Rev 2012, 11(10):21265.
51. Sasaki H., Matsui Y. Epigenetic events in mammalian germ-cell development: reprogramming and beyond. Nat Rev Genet 2008, 2008(2):129-140.
52. Gu P., Xu X., Le Menuet D., Chung A.C., Cooney A.J. Differential recruitment of methyl CpG-binding domain factors and DNA methyltransferases by the orphan receptor germ cell nuclear factor initiates the repression and silencing of Oct4. Stem Cells 2011, 29(7):1041-1051.
53. Pawlak M., Jaenisch R. De novo DNA methylation by Dnmt3a and Dnmt3b is dispensable for nuclear reprogramming of somatic cells to a pluripotent state. Genes Dev 2011, 25(10):1035-1040.
54. Sakaue M., Ohta H., Kumaki Y., et al. DNA methylation is dispensable for the growth and survival of the extraembryonic lineages. Curr Biol 2010, 20(16):1452-1457.
55. Challen G.A., Sun D., Jeong M., et al. Dnmt3a is essential for hematopoietic stem cell differentiation. Nat Genet 2011, 44(1):23-31.
56. Schiedlmeier B., Santos A.C., Ribeiro A., et al. HOXB4's road map to stem cell expansion. Proc Natl Acad Sci U S A 2007, 104(43):16952-16957.
57. Shen Y., Zhu Y.M., Fan X., et al. Gene mutation patterns and their prognostic impact in a cohort of 1185 patients with acute myeloid leukemia. Blood 2011, 118(20):5593-5603.
58. Trowbridge J.J., Sinha A.U., Zhu N., Li M., Armstrong S.A., Orkin S.H. Haploinsufficiency of Dnmt1 impairs leukemia stem cell function through derepression of bivalent chromatin domains. Genes Dev 2012, 26(4):344-349.
59. Oh I.H., Humphries R.K. Concise review: multidimensional regulation of the hematopoietic stem cell state. Stem Cells 2012, 30(1):82-88.
60. Luo L., Han Z. Leukemia stem cells. Int J Hematol 2006, 84(2):123-127.
61. Passegue E., Jamieson C.H., Ailles L.E., Weissman I.L. Normal and leukemic hematopoiesis: are leukemias a stem cell disorder or a reacquisition of stem cell characteristics?. Proc Natl Acad Sci U S A 2003, 100(Suppl 1):11842-11849.
62. Laird P.W., Jackson-Grusby L., Fazeli A., et al. Suppression of intestinal neoplasia by DNA hypomethylation. Cell 1995, 81(2):197-205.
63. Gilliland D.G. Molecular genetics of human leukemias: new insights into therapy. Semin Hematol 2002, 39(4 Suppl 3):6-11.
64. Hu J., Zhou G.B., Wang Z.Y., Chen S.J., Chen Z. Mutant transcription factors and tyrosine kinases as therapeutic targets for leukemias: from acute promyelocytic leukemia to chronic myeloid leukemia and beyond. Adv Cancer Res 2007, 98:191-220.
65. Vardiman J.W., Thiele J., Arber D.A., et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009, 114(5):937-951.
66. Hollink I.H.I.M., Feng Q., Danen-van Oorschot A.A., et al. Low frequency of DNMT3A mutations in pediatric AML, and the identification of the OCI-AML3 cell line as an in vitro model. Leukemia 2011, 26(2):371-373.
67. Jankowska A.M., Makishima H., Tiu R.V., et al. Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A. Blood 2011, 118(14):3932-3941.
68. Couronné L., Bastard C., Bernard O.A. TET2 and DNMT3A mutations in human T-cell lymphoma. N Engl J Med 2012, 366(1):95-96.
69. Abdel-Wahab O., Pardanani A., Rampal R., Lasho T.L., Levine R.L., Tefferi A. DNMT3A mutational analysis in primary myelofibrosis, chronic myelomonocytic leukemia and advanced phases of myeloproliferative neoplasms. Leukemia 2011, 25(7):1219-1220.
70. Stegelmann F., Bullinger L., Schlenk R.F., et al. DNMT3A mutations in myeloproliferative neoplasms. Leukemia 2011, 25(7):1217-1219.
71. Ding L., Ley T.J., Larson D.E., et al. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature 2012, 481(7382):506-510.
72. Argiropoulos B., Humphries R.K. Hox genes in hematopoiesis and leukemogenesis. Oncogene 2007, 26(47):6766-6776.
73. Falini B., Gionfriddo I., Cecchetti F., Ballanti S., Pettirossi V., Martelli M.P. Acute myeloid leukemia with mutated nucleophosmin (NPM1): any hope for a targeted therapy?. Blood Rev 2011, 25(6):247-254.
74. Falini B., Martelli M.P., Bolli N., et al. Acute myeloid leukemia with mutated nucleophosmin (NPM1): is it a distinct entity?. Blood 2011, 117(4):1109-1120.
75. Grisendi S., Mecucci C., Falini B., Pandolfi P.P. Nucleophosmin and cancer. Nat Rev Cancer 2006, 6(7):493-505.
76. Patel J.P., Gonen M., Figueroa M.E., et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med 2012, 366(12):1079-1089.
77. Ghoshal K., Bai S. DNA methyltransferases as targets for cancer therapy. Drugs Today 2007, 43(6):395-422.
78. Schoofs T., Muller-Tidow C. DNA methylation as a pathogenic event and as a therapeutic target in AML. Cancer Treat Rev 2011, 37(1):25.
79. Alva A.S., Hahn N.M., Aparicio A.M., Singal R., Yellapragada S., Sonpavde G. Hypomethylating agents for urologic cancers. Future Oncol 2011, 7(3):447-463.
80. Negrotto S., Ng K.P., Jankowska A.M., et al. CpG methylation patterns and decitabine treatment response in acute myeloid leukemia cells and normal hematopoietic precursors. Leukemia 2012, 26(2):244-254.
81. Fathi A.T., Abdel-Wahab O. Mutations in epigenetic modifiers in myeloid malignancies and the prospect of novel epigenetic-targeted therapy. Adv Hematol 2012, 2012:469592.
82. Song S.H., Han S.W., Bang Y.J. Epigenetic-based therapies in cancer: progress to date. Drugs 2011, 71(18):2391-2403.
83. Platzbecker U., Wermke M., Radke J., et al. Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial. Leukemia 2012, 26(3):381-389.
84. Champion C., Guianvarc'h D., Senamaud-Beaufort C., et al. Mechanistic insights on the inhibition of c5 DNA methyltransferases by zebularine. PLoS One 2010, 5(8).
85. Chen M., Shabashvili D., Nawab A., et al. DNA methyltransferase inhibitor, zebularine, delays tumor growth and induces apoptosis in a genetically engineered mouse model of breast cancer. Mol Cancer Ther 2012, 11(2):370-382.
86. Beumer J.H., Eiseman J.L., Parise R.A., et al. Pharmacokinetics, metabolism, and oral bioavailability of the DNA methyltransferase inhibitor 5-fluoro-2'-deoxycytidine in mice. Clin Cancer Res 2006, 12(24):7483-7491.
87. Reither S., Li F., Gowher H., Jeltsch A. Catalytic mechanism of DNA-(cytosine-C5)-methyltransferases revisited: covalent intermediate formation is not essential for methyl group transfer by the murine Dnmt3a enzyme. J Mol Biol 2003, 329(4):675-684.
88. Gowher H., Jeltsch A. Mechanism of inhibition of DNA methyltransferases by cytidine analogs in cancer therapy. Cancer Biol Ther 2004, 3(11):1062-1068.
89. Huang Y.W., Kuo C.T., Stoner K., Huang T.H., Wang L.S. An overview of epigenetics and chemoprevention. FEBS Lett 2011, 585(13):2129-2136.
90. Lyko F., Brown R. DNA methyltransferase inhibitors and the development of epigenetic cancer therapies. J Natl Cancer Inst 2005, 97(20):1498-1506.
91. Stathis A., Hotte S.J., Chen E.X., et al. Phase I study of decitabine in combination with vorinostat in patients with advanced solid tumors and non-Hodgkin's lymphomas. Clin Cancer Res 2011, 17(6):1582-1590.
92. Baer M.R., Gojo I. Novel agents for the treatment of acute myeloid leukemia in the older patient. J Natl Compr Canc Netw 2011, 9(3):331-335.
93. Jones P.A., Baylin S.B. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002, 3(6):415-428.
94. Saint-Martin C., Leroy G., Delhommeau F., et al. Analysis of the Ten-Eleven Translocation 2 (TET2) gene in familial myeloproliferative neoplasms. Blood 2009, 114(8):1628-1632.
95. Langemeijer S.M.C., Kuiper R.P., Berends M., et al. Acquired mutations in TET2 are common in myelodysplastic syndromes. Nat Genet 2009, 41(7):838-842.